α_1肾上腺素能受体阻滞剂多沙唑嗪治疗III型前列腺炎的临床观察  

Clinical application of α_1 adrenoceptor antagonist doxazosin for chronic non-bacterial prostatitis

作　　者：朱伟[1] 董占宇[1] 

机构地区：[1]北京师范大学医院外科,北京100875

出　　处：《中国现代医学杂志》2014年第31期76-78,共3页China Journal of Modern Medicine

摘　　要：目的探讨α1肾上腺素能受体阻滞剂多沙唑嗪治疗慢性非细菌性前列腺炎/慢性盆底疼痛综合征(CP/CPPS)的有效性及安全性。方法采用开放、自身对照的临床试验方法,应用多沙唑嗪4 mg,每日1次,对39例诊断为CP/CPPS的患者进行了为期4周的治疗。以美国国立卫生院慢性前列腺炎症状评分(NIH-CPSI)、前列腺液(EPS)WBC计数为疗效指标,对其有效性及安全性进行观察。结果治疗4周后,按症状改善评价,39例中治愈2例(5.1%),显效10例(25.6%),有效20例(51.3%),无效7例(17.9%)。总显效率为30.8%,总有效率为82.1%。治疗4周后,受试者NIH-CPSI总评分、疼痛评分、排尿评分、生活质量评分及EPS中WBC计数与治疗前相比,差异有统计学意义(P<0.01)。1例有轻度头晕,不良反应发生率2.6%。结论多沙唑嗪有效地缓解III型前列腺炎患者的疼痛不适症状和排尿症状、改善患者的生活质量和减少EPS中WBC,达到较好的疗效。[ Objective ] To study the efficacy and safety of α1 adrenoceptor antagonist Doxazosin in the treatment of chronic non-bacterial prostatitis. [Methods] An opened, self -controlled, clinical trial was conducted. Thirty- nine cases of patients who had been diagnosed as chronic non-bacterial prostatitis （NBP） were treated with Doxa- zosin （4 mg once a day） for 4 weeks. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index （NIH-CPSI） and the WBC in the examination of prostatic secretion （EPS） after the treatment. [Results] After 4 weeks therapy, the total effective rate was 82.1% in the whole group. After treatment, NIH-CPSI total score, pain score, urinary symptoms score and QOL score were averagely decreased（P 〈0.01）. There was a statistically significant difference in WBC count（P 〈0.01）. The clinical adverse rate was 2.6%, including 1 case of mild dizziness. [Conclu- sion ] α1 adrenoceptor antagonist Doxazosin is effective and safe for the treatment of chronic non-bacterial prostatitis.

关 键 词：慢性前列腺炎 多沙唑嗪 Α1受体阻滞剂 

分 类 号：R697.33[医药卫生—泌尿科学]